PEDIATRICS Vol. 70 No. 4 October 1982, pp. 613-619
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tada, H.
Right arrow Articles by Mayumi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tada, H.
Right arrow Articles by Mayumi, M.

Combined Passive and Active Immunization for Preventing Perinatal Transmission of Hepatitis B Virus Carrier State

Hiroshi Tada MD1, Masahiko Yanagida MD1, Jun Mishina MD1, Toshi Fujii MD1, Kiyoshi Baba BS1, Shuko Ishikawa BS1, Shinobu Aihara BS1, Fumio Tsuda BS1, Yuzo Miyakawa MD1, and Makoto Mayumi MD1

1 Department of Obstetrics, Tokyo Metropolitan Tsukiji Maternity Hospital, Tokyo; Hepatitis Division, Tokyo Metropolitan Institute of Medical Science, Tokyo; Third Department of Internal Medicine, University of Tokyo, Tokyo; and Immunology Division, Jichi Medical School, Tochgi-ken, Japan

Prevention of perinatal transmission of hepatitis B virus carrier state in neonates at high risk was attempted by a combined passive and active immunization. Immediately after delivery, ten babies born to mothers who were asymptomatic carriers of hepatitis B surface antigen (HB8Ag) and seropositive for hepatitis B e antigen received an intravenous injection of F(ab’)2 fragments (200 IU) derived from hepatitis B immune globulin (HBIG). On the following day, none of them revealed detectable levels of the antibody to HB8Ag in their sera, and received an intramuscular injection of HBIG (200 IU) which was repeated at 2 and 4 months of age. Vaccination with 40 µg of purified, formalin-inactivated HB8Ag particles was given to the nine babies at three months and repeated at 4, 5, and 7 months after birth. All of them maintained detectable levels of the antibody and escaped infection throughout the first 12 months of their lives. The one baby who did not have detectable F(ab’)2 in serum for 24 hours developed persistent HB8 antigenemia which was noticed as early as seven days after birth.

Submitted on February 12, 1981
Accepted on March 25, 1982




This article has been cited by other articles:


Home page
 BMJHome page
P M Grosheide, J W Wladimiroff, R A Heijtink, J A Mazel, G C M L Christiaens, A S M Nuijten, and S W Schalm
Proposal for routine antenatal screening at 14 weeks for hepatitis B surface antigen
BMJ, November 4, 1995; 311(7014): 1197 - 1199.
[Abstract] [Full Text]